Credit: Shutterstock photoSutro Biopharma, a Phase 1 biotech developing immunotherapies for multiple myeloma and NHL, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering.
The South San Francisco, CA-based company was founded in 2003 and booked $33 million in revenue for the 12 months ended June 30, 2018. It plans to list on the Nasdaq under the symbol STRO. Sutro Biopharma filed confidentially on June 1, 2018. Cowen and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
The article NHL immunotherapy biotech Sutro Biopharma files for a $75 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
